OBJECTIVE: The pharmacological self-management of novel psychoactive substance (NPS)-induced psychopathological consequences represents a fast growing phenomenon. This is facilitated by the frequent sharing of NPS intake experiences online and by the ease of access to a range of psychotropic medications from both the online and street market. Olanzapine is anecdotally reported by Web users to be the most frequent self-prescribed medication to cope with NPS-induced psychoses. Hence, we aimed here at better assessing olanzapine use/misuse for this purpose. METHODS: Exploratory qualitative searches of 163 discussion fora/specialized websites have been carried out in four languages (English, German, Spanish, and Italian) in the time frame November 2012-2013. RESULTS: Most NPS-users allegedly self administer with olanzapine to manage related psychotic crises/"bad trips". This may be typically taken only for a few days, at a dosage range of 5-50 mg/day. CONCLUSIONS: Only a few research studies have formally assessed the effectiveness of olanzapine and indeed of other second-generation antipsychotics to treat NPS-induced psychosis. Olanzapine was suggested here from a range of pro drug websites as being the "ideal" molecule to terminate "bad trips". Health professionals should be informed about the risks related to olanzapine misuse.

Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms / Valeriani, Giuseppe; Corazza, Ornella; Bersani, FRANCESCO SAVERIO; Melcore, Claudia; Metastasio, A; Bersani, Giuseppe; Schifano, F.. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - STAMPA. - 30:4(2015), pp. 249-254. [10.1002/hup.2431]

Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms

VALERIANI, GIUSEPPE;CORAZZA, ORNELLA;BERSANI, FRANCESCO SAVERIO;MELCORE, CLAUDIA;BERSANI, Giuseppe;
2015

Abstract

OBJECTIVE: The pharmacological self-management of novel psychoactive substance (NPS)-induced psychopathological consequences represents a fast growing phenomenon. This is facilitated by the frequent sharing of NPS intake experiences online and by the ease of access to a range of psychotropic medications from both the online and street market. Olanzapine is anecdotally reported by Web users to be the most frequent self-prescribed medication to cope with NPS-induced psychoses. Hence, we aimed here at better assessing olanzapine use/misuse for this purpose. METHODS: Exploratory qualitative searches of 163 discussion fora/specialized websites have been carried out in four languages (English, German, Spanish, and Italian) in the time frame November 2012-2013. RESULTS: Most NPS-users allegedly self administer with olanzapine to manage related psychotic crises/"bad trips". This may be typically taken only for a few days, at a dosage range of 5-50 mg/day. CONCLUSIONS: Only a few research studies have formally assessed the effectiveness of olanzapine and indeed of other second-generation antipsychotics to treat NPS-induced psychosis. Olanzapine was suggested here from a range of pro drug websites as being the "ideal" molecule to terminate "bad trips". Health professionals should be informed about the risks related to olanzapine misuse.
2015
drug misuse; drug-induced psychoses; novel psychoactive substances; olanzapine; online reports
01 Pubblicazione su rivista::01a Articolo in rivista
Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms / Valeriani, Giuseppe; Corazza, Ornella; Bersani, FRANCESCO SAVERIO; Melcore, Claudia; Metastasio, A; Bersani, Giuseppe; Schifano, F.. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - STAMPA. - 30:4(2015), pp. 249-254. [10.1002/hup.2431]
File allegati a questo prodotto
File Dimensione Formato  
Valeriani_Olanzapine_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 164.93 kB
Formato Adobe PDF
164.93 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/867531
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 30
social impact